Cells optimised to produce substance that holds potential to improve ‘healthy ageing’

The population on Earth is increasingly growing and people are expected to live longer in the future. Thus, better and more reliable therapies to treat human diseases such as Alzheimer’s and cardiovascular diseases are crucial. To cope with the challenge of ensuring healthy ageing, a group of international scientists investigated the potential of biosynthesising several polyamines and polyamines analogues with already known functionalities in treating and preventing age-related diseases.

Therefore, the researchers instead decided to open their biochemical toolbox and use classical metabolic engineering strategies to engineer the yeast metabolism to produce polyamines and polyamines analogues.

“This group of molecules has huge potential in addressing important societal challenges and it seemed logical to try and produce them with the help of biology,” emphasises Jiufu Qin, Senior Researcher at The Novo Nordisk Foundation Center for Biosustainability, DTU.

The team of scientists explored seven biosynthetic routes that synthesises spermidine from arginine or ornithine and by employing flux balance analysis they could estimate the maximum theoretical yield of each pathway.

After establishing the most efficient pathway for spermidine and systematically engineering the cellular metabolism of yeast they managed to ultimately reach a production of spermidine at titers 2.3 gram per liter on lab scale. An initial result that proves the potential of utilising nature’s large and diverse reservoir of biochemical tools to push forward products that can meet the challenges of population ageing and a lack of sufficient food supplies.

“We expect that our studies lay the groundwork for fermentation-based manufacture of diverse polyamines and polyamine analogues to further unlock this field’s potential for pharmacological and agricultural applications, “says Jens Nielsen, Professor at Chalmers University of Technology and CEO at BioInnovation Institute.

But all that glitter is not gold and an obstacle such as low enzyme activity causing feedback regulation and thereby compromising the product yield still needs to be overcome.

Even though the strain might need to be improved further, scale-up towards commercial production is already ongoing since the current titers are deemed sufficient for initialising production.

The company Chrysea Labs has been established based on this scientific study and the company has a mission of developing healthy lifespan nutritional interventions by ameliorating the natural occurring anti-ageing mechanism autophagy that recycle the cellular process, which is critical for maintaining cell health, renewal and survival.

Since the market is expected to grow in the coming years and only a few competitors are currently present in the field there might be a window of opportunity for Chrysea Labs to be a frontrunner in ensuring healthy ageing.

###